Graduation arc · Parkinson’s Cure Discovery · Invent Deposition #3526 (2017) → Parkinson’s Mechanism Analysis — Proof of Function #1

The 2017 seed-line

In 2017, the entry that became Parkinson’s Mechanism Analysis — Proof of Function #1 was written down as Invent Deposition #3526:

“Electronic muscle pulse therapy for atrophy patients help me walk? some organic / some post organic measure electronic muscle pulse therapy for atrophy patients step 3 super infomercial for medical if i saw it on tv it has to be real disabled tendon repair and extensions step 2 chicken cat transfer alternate cartilage transplant organic fiber optic nerve conductors step 1 non evasive neurological where do you have trouble and electronic pulse for prolonged wheel chair patients,.”— © 2017 Christopher Gabriel Brown

What changed between 2017 and the product on the shelf

The 2017 entry tackled the motor-control problem at the muscle-and-nerve layer — patients who need help with movement, and a closed-loop electronic pulse therapy concept. The Proof of Function moves that framing upstream to the dopaminergic pathway: a mechanism-analysis grid traces candidate pathway nodes, scores them against the closed-loop rubric used across the cure-discovery portfolio, and packages the result for partner-team evaluation. The redaction layer lets a reviewer work with the IP without exposing the AES-encrypted source archive. Patent-pending; design targets only — no warranted clinical outcome.

Where it sits in the four-step framework

• Proof of Function — this article’s SKU. A working write-up against representative inputs; available for licensing review at Parkinson’s Mechanism Analysis — Proof of Function #1.
• Tech Validation — bench data and reproducibility under an evaluation licence.
• Eval Licence — supervised use of the IP package by a partner team.
• Full Acquisition — the patent application, prior-art binder, and prosecution file transfer in full.

→ Open the Proof of Function: Parkinson’s Mechanism Analysis — Proof of Function #1

Provenance: published 2017 in the Invent Depositions collection (Invent Deposition #3526); part of an intellectual-property portfolio with U.S. patent applications dating to 2012; independently timestamped by the Internet Archive. Patent-pending. Design targets, not warranted performance. First to market — documented public offering, not a determination of patent priority.